{"id":"sabin-strain-inactivated-poliovirus-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL2107962","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine contains inactivated poliovirus strains, which are unable to cause disease but can still trigger an immune response. The immune system recognizes the inactivated virus as foreign and mounts a response to eliminate it, providing immunity against future poliovirus infections.","oneSentence":"The Sabin Strain Inactivated Poliovirus Vaccine works by exposing the body to a weakened form of the poliovirus, stimulating an immune response to provide protection against poliovirus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:13.590Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis"}]},"trialDetails":[{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT07297186","phase":"PHASE3","title":"Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2017-08-21","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT05850364","phase":"PHASE3","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-05-22","conditions":"Poliomyelitis, Polio","enrollment":1442},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT06460545","phase":"PHASE4","title":"Phase IV Study of Concomitant Administration of the sIPV and HepA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-06-15","conditions":"Polio, Hepatitis A","enrollment":2000},{"nctId":"NCT05386810","phase":"PHASE3","title":"Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-11-05","conditions":"Poliomyelitis","enrollment":1572},{"nctId":"NCT05327426","phase":"PHASE1","title":"Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-04-01","conditions":"Poliomyelitis","enrollment":19},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT04220515","phase":"PHASE4","title":"Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-02-08","conditions":"Poliomyelitis","enrollment":49731},{"nctId":"NCT04224519","phase":"PHASE4","title":"Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-04-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04614597","phase":"","title":"A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2020-10-29","conditions":"Poliomyelitis","enrollment":774},{"nctId":"NCT04386707","phase":"PHASE3","title":"Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-05-11","conditions":"Poliomyelitis","enrollment":1300},{"nctId":"NCT04638985","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-13","conditions":"Vaccine","enrollment":600},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT03546634","phase":"PHASE4","title":"Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2018-05-24","conditions":"Poliomyelitis","enrollment":280},{"nctId":"NCT03597919","phase":"PHASE4","title":"A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2018-05-28","conditions":"Poliomyelitis","enrollment":560},{"nctId":"NCT03169725","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-05-31","conditions":"Poliomyelitis","enrollment":1417},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03526978","phase":"PHASE3","title":"An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-08-08","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT02985320","phase":"PHASE1, PHASE2","title":"Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2016-10","conditions":"Poliomyelitis","enrollment":708},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sabin Strain Inactivated Poliovirus Vaccine","genericName":"Sabin Strain Inactivated Poliovirus Vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Sabin Strain Inactivated Poliovirus Vaccine works by exposing the body to a weakened form of the poliovirus, stimulating an immune response to provide protection against poliovirus infection. Used for Prevention of poliomyelitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}